SCHEMBL717248

SCHEMBL717248

Cc1nn(-c2ccccc2Cl)cc1C=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CYP1A2 P05177 1/20 0.40
GLA P06280 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PTGS2 P35354 1/20 0.39
BCHE P06276 1/20 0.39
ALDH1A1 P00352 5/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
KMT2A Q03164 4/20 0.38
KDM4E B2RXH2 3/20 0.38
MEN1 O00255 3/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
PKM P14618 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716273 0.79 ALDH1A1 (0.52) ADORA3CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL14996591 0.78 CYP1A2 (0.44) PARP1ADORA3CYP1A2GLACYP3A4
SCHEMBL15331215 0.78 PARP1 (0.44) PARP1ADORA3CYP2C9PTGS2BCHE
SCHEMBL1803648 0.78 KCNH2 (0.41) NPSR1PTGS2ALDH1A1SMN1; SMN2KMT2A
SCHEMBL719535 0.77 PTGS2 (0.63) NPSR1PTGS2ALDH1A1SMN1; SMN2KMT2A
SCHEMBL11972479 0.77 POLB (0.37) NPSR1PTGS2ALDH1A1SMN1; SMN2KMT2A
SCHEMBL20345173 0.77 SMN1; SMN2 (0.34) PTGS2ALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL12871887 0.76 PDE4B (0.44) PARP1ADORA3CYP1A2GLACYP3A4
SCHEMBL12859489 0.76 CYP1A2 (0.41) PARP1ADORA3CYP1A2GLACYP3A4
SCHEMBL1842088 0.76 PTGS2 (0.35) PTGS2ALDH1A1SMN1; SMN2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP PARP1 4426/4885ADORA3 2906/4885CYP1A2 774/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP PARP1 4426/4885ADORA3 2906/4885CYP1A2 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.